McClellan's FDA Team
This article was originally published in RPM Report
When Mark McClellan became FDA commissioner in late 2002, he brought with him a cadre of like-minded managers and policy advisors. Many were economists; all were advocates for private-sector innovation. Most have departed from FDA. Their departures may have some short-term political benefits for the agency; but they leave a legacy of economic interest in the way FDA works and affects society.
You may also be interested in...
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
No matter who wins, the 2008 Presidential election means there will be widespread personnel changes across key federal health agencies. Two ex-FDA officials look particularly ready to resurface should the Democrats take back the White House.
FDA has a new chief operating officer and medical officer. The appointments reflect the challenges of a lean budget and calls for a chief scientist from the Institute of Medicine.